



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention

Print Date: 6/26/20

Title: OMB 0920-1215 Awardee Lead Profile Assessment (ALPA)
Project Id: 0900f3eb81b58ce0
Accession #: NCEH-LPPEHTB-5/27/20-58ce0
Project Contact: Ruckart_Perri A. (afp4)
Organization: NCEH/ATSDR/DEHSP/LPPEHTB
Status: **Pending Clearance**
Intended Use: **Project Determination**
Estimated Start Date: 02/01/2021
Estimated Completion Date: 01/31/2024
CDC/ATSDR HRPO/IRB Protocol #:
OMB Control #:

Determinations

Determination	Justification	Completed	Entered By & Role
HSC: Does NOT Require HRPO Review	Not Research / Other <i>45 CFR 46.102(l)</i> Program Evaluation Quality Assurance / Improvement	6/26/20	Davis_Stephanie I. (sgd8) CIO HSC

Description & Funding

Description

Priority: Standard

Date Needed: 06/05/2020

Determination Start Date: 05/28/20

Description:

This is a revision request of a currently approved OMB protocol #0920-1215 (Expiration Date 02/28/2021). The Awardee Lead Profile Assessment (ALPA) data collection instrument will be used to: 1) identify common characteristics of funded childhood lead poisoning prevention programs and 2) inform guidance, resource development, and technical assistance activities conducted by the CDC Childhood Lead Poisoning Prevention Program (CLPPP) in support of the ultimate goal, which is blood lead elimination in children. Assessment findings will be shared on the CDC CLPPP website and in response to inquiries by the public, press, and Congress. The dissemination of results will support the ability for both funded and non-funded jurisdictions to: 1) identify policies and other factors that support or hinder childhood lead poisoning prevention efforts, 2) understand what strategies are being used by funded state and local governments (or their bona fide fiscal agents) to implement childhood lead poisoning prevention activities, and 3) use this knowledge to develop and apply similar strategies to support the national agenda to eliminate childhood lead poisoning. Changes included modifying survey questions with text box answers to gateway questions with multiple choice answer options. Additionally, specific terms and phrases were revised for conciseness and clarification and questions about primary prevention and lead elimination were added to the survey.

IMS/CIO/Epi-Aid/Chemical Exposure Submission: No

IMS Activation Name: Not selected

CIO Emergency Response Name: Not selected

Epi-Aid Name: Not selected

Assessment of Chemical Exposure Name: Not selected

Goals/Purpose

The purpose of this annual assessment under the cooperative agreement is to identify: 1) jurisdictional legal frameworks governing CDC-funded childhood lead poisoning prevention programs in the United States and 2) strategies for implementing childhood lead poisoning prevention activities in the United States.

Objective:

The ALPA information collection will serve to 1) identify common characteristics of awarded childhood lead poisoning prevention programs and 2) inform guidance and resource development in support of the ultimate elimination goal. The dissemination of results obtained from this information collection will enable jurisdictions to 1) identify policies and other factors that support or hinder childhood lead poisoning prevention efforts; 2) understand what strategies are being used by funded state and local governments (or their bona fide fiscal agents) to implement childhood lead poisoning prevention activities; and 3) use this knowledge to develop and apply similar strategies to support the national agenda to eliminate childhood lead poisoning. Both funded and non-funded jurisdictions will be able to apply these principles to their childhood lead poisoning prevention programs. Findings will be shared on CDC's CLPPP website and in response to inquiries by the public, press, and Congress.

Activities or Tasks: New Collection of Information, Data, or Biospecimens

Target Populations to be Included/Represented: Other

Tags/Keywords: Lead Poisoning

CDC's Role: Activity originated and designed by CDC staff, or conducted at the specific request of CDC, or CDC staff will approve study design and data collection as a condition of any funding provided

Method Categories: Survey

Methods: Each recipient has one project manager for lead poisoning prevention activities. Each project manager will complete the questionnaire in his or her official capacity. The ALPA questionnaire will use the EpiInfo functionality as the primary method for respondents to complete the information. The link will be sent via an invitation email by a CDC staff member to the attention of all project managers of the funded programs approximately 150 days before the end of the annual budget period. A follow-up email will be sent to the attention of all project managers approximately 130 days before the end of the annual budget period. Respondents who do not want to complete the online web questionnaire will be able to complete the Word questionnaire that will be emailed to them by a CDC staff member.

Collection of Info, Data or Biospecimen: Via survey that will have a web-based on paper-based option

Expected Use of Findings/Results: Assessment findings will be shared on the HHLPPP CDC CLPPP website and in response to inquiries by the public, press, and Congress. The dissemination of results will support the ability for both funded and non-funded jurisdictions to: 1) identify policies and other factors that support or hinder childhood lead poisoning prevention efforts, 2) understand what strategies are being used by funded state and local governments (or their bona fide fiscal agents) to implement childhood lead poisoning prevention activities, and 3) use this knowledge to develop and apply similar strategies to support the national agenda to eliminate childhood lead poisoning.

Could Individuals potentially be identified based on Information Collected? No

Funding

Funding Type	Funding Title	Funding #	Original Budget Yr	# Years Award
CDC Cooperative Agreement	Childhood Lead Poisoning Prevention Projects, State and Local Childhood Lead Poisoning Prevention and Surveillance of Blood Lead Levels in Children	CDC-RFA-EH18-1806	2018	3
CDC Cooperative Agreement	Lead Poisoning Prevention- Childhood Lead Poisoning Prevention	CDC-RFA-EH17-1701PPHF17	2017	4

HSC Review

HSC Attributes

Program Evaluation	Yes
Quality Assurance / Improvement	Yes

Regulation and Policy

Do you anticipate this project will be submitted to the IRB office No

Estimated number of study participants

Population - Children

Population - Minors

Population - Prisoners

Population - Pregnant Women

Population - Emancipated Minors

Suggested level of risk to subjects Do you anticipate this project will be exempt research or non-exempt research

Requested consent process wavers

Informed consent for adults	No Selection
Children capable of providing assent	No Selection
Parental permission	No Selection
Alteration of authorization under HIPPA Privacy Rule	No Selection

Requested documents of informed consent

Informed consent for adults	No Selection
-----------------------------	--------------

Children capable of providing assent No Selection

Parental permission No Selection

Consent process shown in an understandable language

Reading level has been estimated No Selection

Comprehension tool is provided No Selection

Short form is provided No Selection

Translation planned or performed No Selection

Certified translation / translator No Selection

Translation and back-translation to/from target language(s) No Selection

Other method No Selection

Clinical Trial

Involves human participants No Selection

Assigned to an intervention No Selection

Evaluate the effect of the intervention No Selection

Evaluation of a health related biomedical or behavioral outcome No Selection

Registerable clinical trial No Selection

Other Considerations

Exception is requested to PHS informing those bested about HIV serostatus No Selection

Human genetic testing is planned now or in the future No Selection

Involves long-term storage of identifiable biological specimens No Selection

Involves a drug, biologic, or device No Selection

Conducted under an Investigational New Drug exemption or Investigational Device Exemption No Selection

Institutions & Staff

Institutions

Institutions yet to be added

Staff

Staff Member	SIQT Exp. Date	CITI Biomedical Exp. Date	CITI Social & Behavioral Exp. Date	CITI Good Clinical Practice Exp. Date	Staff Role	Email	Phone	Organization
Kelly Dyke	03/12/2021				Data Owner	nfn8@cdc.gov	404-498-1215	PROGRAM SERVICES
Perri Ruckart	05/02/2021	11/07/2020	11/20/2020		Program Official	afp4@cdc.gov	770-488-3808	LEAD POISONING PREVENTION AND ENVIRONMENTAL HEALTH TRACKING BRANCH
Rio Schondelmeyer	05/27/2023				Data Use Contact	prw8@cdc.gov	404-498-2797	PROGRAM DEVELOPMENT, COMMUNICATIONS AND EVALUATION

Data

DMP

Proposed Data Collection Start Date: 6/1/21

Proposed Data Collection End Date: 6/28/24

Proposed Public Access Level: Public, Restricted

Restricted Details:

Data Use Type: Data Sharing Agreement

Data Use Type URL:

Data Use Contact:

Public Access Justification: de-identified data can be shared

How Access Will Be Provided for Data: aggregate data will be publicly available on CDC CLPPP website and additional data may be shared upon request for approved purposes via data use agreement

Plans for Archival and Long Term Preservation:

Spatiality

Spatiality (Geographic Locations) yet to be added

Dataset

Dataset Title	Dataset Description	Data Publisher /Owner	Public Access Level	Public Access Justification	External Access URL	Download URL	Type of Data Released	Collection Start Date	Collection End Date
Dataset yet to be added...									



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention